Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Neurobiol Aging. 2014 Mar 11;35(9):2096–2106. doi: 10.1016/j.neurobiolaging.2014.03.006

Fig. 4.

Fig. 4

Boxplots of the FDG ratio (partial volume corrected [PVCY]) in the AD-signature meta-ROI among elderly (age ≥70 years) CN, MCI, and AD subjects and among CN APOE ε4 carriers and noncarriers of all ages to demonstrate the relative AD dementia and APOE ε4 effects. AD dementia subjects who were APOE ε4 carriers and amyloid positive were matched to APOE ε4 carrier, amyloid positive MCI subjects, and APOE ε4 carrier CN subjects on age and sex. CN APOE ε4 carriers were matched on age and sex to APOE ε4 non-carriers. Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CN, cognitively normal; FDG, 18F-fluorodeoxyglucose; MCI, mild cognitive impairment; ROI, region of interest.